Arsenic Trioxide in Combination With Cytarabine in Patients With High-risk MDS and Poor-prognosis AML

NCT00195104 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

87

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome

Interventions

DRUG: Arsenic Trioxide (Tricenox)
DRUG: Cytarabine

Sponsor

Weill Medical College of Cornell University